Nothing said here yet.
to join the conversation.
Medicus Pharma (NASDAQ:MDCX) CEO Dr Raza Bokhari will present at BioFuture 2026 in New York and deliver a keynote at the Global Biotechnology Summit 2026 in Abu Dhabi.
Company’s Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu DhabiPHILADELPHIA, Oct.
Nasdaq closes the minimum bid price matter confirming that the Company has regained compliancePHILADELPHIA, Oct.
Medicus Pharma is prioritizing clinical milestones, regulatory progress and potential partnerships across its oncology, dermatology and urology portfolio as it seeks to demonstrate returns on three years of investment.
Medicus Pharma (NASDAQ:MDCX) is positioning its precision oncology-led pipeline for a series of clinical and regulatory milestones, with partnerships and licensing deals central to the next phase of development, the company said in a shareholder update…
Advancing Precision Oncology and Partner-Ready Therapeutic Programs Through Capital-Efficient DevelopmentPHILADELPHIA, Oct.
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss the company’s submission of an optimized seamless Phase 2b/3 registration-intent protocol to the U.S. Food and Drug Administration (FDA) for Teverelix®, its investigational…
Medicus Pharma (NASDAQ:MDCX) has submitted a seamless Phase 2b/3 registration-intent protocol to the US Food and Drug Administration for Teverelix, its long-acting GnRH antagonist for advanced prostate cancer patients at increased cardiovascular risk.
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategyPHILADELPHIA, Sept.
Medicus Pharma (NASDAQ:MDCX) said it will focus future internally sponsored clinical development of SkinJect exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and will conclude further development in sporadic/nodular basal cell carcinoma.
Medicus Pharma Ltd.
Decision advances Company’s previously announced capital-efficient development strategy by concentrating resources on FDA-authorized, SKNJCT-005, NDA-enabling, Registrational Phase 2b Study in Gorlin syndrome patients and concluding further development of nodular Basal Cell CarcinomaPHILADELPHIA, Sept.